TRALA trial

Chief investigator - Dr Kim Orchard, University Hospital Southampton NHS Foundation Trust
A phase I study of targeted radiotherapy alone for stem cell transplant conditioning in systemic AL amyloidosis
Amount awarded: £296,702
Award start date: 02 Mar 2015
Recruitment start date: 08 Jul 2016
Award duration: 3 years (40 months)

Amyloidosis is a condition where the bone marrow makes abnormal plasma cells, which produce a protein called amyloid. Amyloid can build up in body tissues, affecting the way organs work.

This study is for people who have a type of amyloidosis called systemic amyloid light-chain (AL) amyloidosis - the most common type of amyloidosis. People with Myeloma may develop amyloidosis.

Chemotherapy or high dose chemotherapy and a stem cell transplant are usually given to treat AL amyloidosis. Although this approach is successful, many people with AL suffer side effects from their treatment, such as serious infections and bleeding from the gut.

In this study, researchers want to look at using targeted radiotherapy in place of high dose chemotherapy. Radiotherapy can be given directly to the bone marrow, which destroys the abnormal cells leaving healthy cells relatively untouched. Delivering treatment in this more targeted way may alleviate the side effects seen from standard AL treatment.

The aims of this study are to:

  • See how safe it is to use targeted radiotherapy as part of a stem cell transplant
  • Learn more about the side effects
  • See how well it works

You may be eligible to join this trial if:

  • You have just been diagnosed with systemic AL amyloidosis or it has come back after previous treatment (recurrent systemic AL amyloidosis)
  • You have a body organ that is not functioning properly because of your systemic AL amyloidosis
  • You are suitable to have an autologous stem cell transplant
  • You are aged 18 years or older